News Releases

ALPN-202 Preclinical Data Presented at the Society for Immunotherapy of Cancer’s ( SITC ) 33 rd Annual Meeting Supports First-In-Class Triple Mechanism of Action for the Treatment of Cancer Company Strengthens Scientific Advisory Board with Slate of Oncology Leaders SEATTLE --(BUSINESS WIRE)--Nov.

SEATTLE --(BUSINESS WIRE)--Nov. 8, 2018-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing innovative treatments for autoimmune/inflammatory diseases and cancer, today provided a corporate update and reported financial results for the third quarter

SEATTLE --(BUSINESS WIRE)--Nov. 5, 2018-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced the company will participate in two upcoming investor

SEATTLE --(BUSINESS WIRE)--Nov. 1, 2018-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced two upcoming poster presentations at the 60 th American Society

Data from experimental models of inflammatory arthritis and multiple sclerosis presented at 2018 ACR/ARHP Annual Meeting and 143 rd Annual Meeting of the American Neurological Association ALPN-101 has completed CMC scale up and is poised to be the first dual ICOS /CD28 antagonist in clinic in Q1

SEATTLE --(BUSINESS WIRE)--Oct. 4, 2018-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced two upcoming poster presentations at the Society for

SEATTLE --(BUSINESS WIRE)--Sep. 25, 2018-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced the company will present at the Ladenburg Thalmann 2018

ALPN-101 preclinical data to be presented at the 2018 ACR/ARHP Annual Meeting and the 143 rd Annual Meeting of the American Neurological Association SEATTLE --(BUSINESS WIRE)--Sep. 24, 2018-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing

SEATTLE --(BUSINESS WIRE)--Aug. 9, 2018-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a company focused on discovering and developing innovative, protein-based immunotherapies targeting the immune synapse to treat cancer, autoimmune/inflammatory, and other diseases, provided a corporate update and

SEATTLE --(BUSINESS WIRE)--Aug. 8, 2018-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a company focused on discovering and developing innovative immunotherapies to treat cancer, autoimmune/inflammatory and other diseases, today reported the grant of an equity inducement award to Mark Litton ,